Safety and Early Efficacy of Involved Field SBRT for Nodal Oligo-Recurrent Prostate Cancer

With the widespread adoption of novel PET agents the group of patients with oligo-recurrent nodal disease is likely to increase significantly. The optimal combination of local and systemic therapy in this patient population is the subject of ongoing clinical investigation. With a favorable toxicity profile, high rates of local control and PSA response, involved field SBRT represents a feasible as well as convenient local therapy treatment option for an elderly patient population.